Regeneron Pharmaceuticals Inc (REGN) News
Latest headlines that mention REGN, newest first · each headline opens the original publisher
- Last price
- $739.57
- Day change
- -0.34%
- Next earnings
- 2026-10-30 BMO
REGN headlines
last 30 daysThe healthcare company will release its third-quarter results next month.
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea. The post Why This Regeneron Eye Rival Just Catapulted More Than 170% appeared first on Investor's Business Daily .
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Also mentioned with REGN
30dHeadlines that tag both tickers
REGN news alerts
Get an alert by email or push when a new headline mentions REGN.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.